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Abstract
Carrion’s disease is a neglected tropical disease caused by Bartonella bacilliformis, a vector-borne pathogen
restricted to the Andean valleys of Peru, Ecuador and Colombia. Carrion’s disease is a biphasic illness; in the acute
phase the case-fatality rate can be as high as 88 %, related to high parasitemia, arriving to almost all erythrocytes,
and secondary bacterial infections close related with the development of transient immunosuppression in the
earlier illness phases. In addition, there are an undefined number of asymptomatic carriers that are reservoirs of the
etiological agent of Carrion’s disease in endemic areas, they make take into account due to they are the
perpetuators of this disease. The actual scenario of Carrion’s disease, in which the illness is arriving to new areas,
due to the expansion of the vector’s distribution, suggests that now may be a crucial time to design a strategy
focusing on its elimination.
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Background
In the last two centuries, the fight against infectious dis-
eases has enormously progressed and the burden of a
number of such diseases has dramatically been reduced,
especially in developed countries. A series of milestones
has marked this progress. The introductions of vaccines
and antimicrobial agents in the 19th and 20th centuries,
respectively, are considered to be the most crucial ad-
vances, with social developments, such as increasing
education levels and improving nutritional status, access
to potable water and improved sanitary environments
also playing an invaluable role.
The eradication of smallpox and advances towards the
eradication of poliomyelitis have been some of the major
goals achieved by vaccination campaigns, and at present,
the eradication of illnesses such as malaria, elephantiasis,
teniasis, measles, mumps, rubella and yaws are red
marked on the international health agenda, being
performed strong efforts to advance towards this object-
ive [1–3].
However, it is important to give attention to several
other neglected diseases, such as Carrion’s disease. This
infectious disease is caused by Bartonella bacilliformis, a
vector-borne pathogen restricted to the Andean valleys
of Peru, Ecuador and Colombia [4]. In Peru, the most af-
fected country, endemic areas account for around 145
000 km2 of the total landmass, where more than 1.6 mil-
lion inhabitants live [4]. Carrion’s disease is a biphasic
illness, and has an acute and a chronic phase; in the
acute phase the case-fatality rate can be as high as 88 %,
in the event of no or delayed in treatment due to high
parasitemia and secondary bacterial infections, which
are associated to a B. bacilliformis induced transient
immunosuppression. However, if the disease is cor-
rectly treated, the case-fatality rate decreases to
around 10 % [4].
According to Peruvian national guidelines, the anti-
biotic treatments in the acute phase of the disease are
chloramphenicol or ciprofloxacin, alone or combined
with cephalosporins or aminoglycosides [5]. Meanwhile,
rifampicin or azithromycin are proposed treatments in
the chronic phase. Although B. bacilliformis is consid-
ered to be highly susceptible to all antibacterial agents
except for quinolones [6, 7] and a recent study reported
a 26 % resistance to ciprofloxacin and a 1 % resistance
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to chloramphenicol [8], in vitro studies have shown that
B. bacilliformis may develop high resistance levels to al-
most all the aforementioned antibiotic agents [9, 10]. It
is perhaps this phenomenon that contributes to the high
case-fatality rate of Carrion’s disease.
The acute phase, so named Oroya fever, mostly affects
previously non-exposed populations, such as children, as
well as specific at-risk populations such as pregnant
women due to the possibility that bacteria can be trans-
ferred through the placenta causing severe fetal compli-
cations including preterm birth, miscarriages, fetal death
and neonatal Oroya fever, among others [4, 11–13].
Meanwhile, the chronic phase, which mainly affects pre-
viously exposed populations, is not life threating and is
characterised by hemangioma-like nodules in the skin
and mucous membranes known as ‘Peruvian wWarts’[4].
These lesions are mainly located in the extremities and
head, possessing a variable morphology. Thus miliary,
mulaire and nodule subdermal lesions have been de-
scribed [4]. Asymptomatic infections are common in
people from endemic areas. Although this phase has an
undefined duration, a previous study reported the isola-
tion of viable B. bacilliformis from blood samples of an
Ecuadorian expatriate with acute splenomegaly and
anemia who had been living out of endemic areas for
three years [14]. Although definitive data about the real
number of asymptomatic carriers, which act as perpetua-
tors of the illness, are not available, Chamberlin et al. have
reported that 45 % of inhabitants in endemic areas under
21 years of age showed previous exposure to the pathogen
[15], using the indirect fluorescent antibody (IFA) method.
Thus, up until now no reservoir other than a human
has been described. Several candidate reservoirs have
been postulated in a number of studies during outbreaks
of Carrion’s disease, from Euphorbiaceae to domestic
and wild rodents. However, B. bacilliformis has never
been identified in these candidate reservoirs [16]. In
addition, studies on the vertical transmission of B. bacil-
liformis in Lutzomyia verrucarum, its main vector, have
shown that high bacterial loads affect the viability of
sandflies, hindering oviposition [17]. Despite control ef-
forts, a resurgence of this infection has occurred [4] and
has seemingly expanded to naive areas. This increase in
infection may be related to the availability of diagnostic
tools, vector expansion, climate change and human ac-
tivities, such as the creation of new agricola areas or
hydroelectric installations which may favours the life-
cycle of Lutzomyia spp. or the creation of new roads and
the increasing product trade, which may result in the ac-
cidental transfer of vectors to new areas, or due to the
introduction of the illness into new areas by migrant
populations from endemic regions. This suggests that
now maybe a crucial time to design a strategy focusing
on the elimination of Carrion’s disease.
Main text
In the late years of the 20th century the actions towards
eradication of different illness were increased. Thus in
1993 a series of infectious diseases were analysed to de-
termine the feasibility of its eradication [18], and in 1997
a series of illness, including Chagas disease or leprosy
were considered as target to be eliminated in 10 years
period. Thus, being needed to establish in a firm manner
the conditions needed to advance towards illness
eradication, in 1997, Dahlem Workshop on the Eradica-
tion of Infectious Diseases was held in Berlin. One of
the main things that came out of it was a series of cri-
teria (Dahlem’s criteria) established to determine the
feasibility of eliminating and eradicating an illness in the
context of global health strategies [19].
Three specific points were considered to be the most
relevant in the way towards diseases’ elimination: effect-
iveness of intervention, availability of sensitive diagnostic
tools and human beings the only vertebrate reservoirs.
Because Carrion’s disease meets all three criteria, it
becomes evident that research efforts need to be
strengthened to design and validate vaccine candidates
to eradicate this disease. The high antibiotic susceptibil-
ity of B. bacilliformis suggests that mass treatment could
lead to the elimination of the illness in some areas, and
to a significant decrease of disease carriers in others.
Additionally, this disease affect a well-delimited geo-
graphically area, being a key factor in the effectiveness of
these actions. The development of molecular and im-
munological tools, including real-time polymerase chain
reaction (PCR), enzyme-linked immunosorbent assays
(ELISAs) and IFAs will allow for efficient diagnosis,
however, the difficulties in their implementation in en-
demic areas, both related with the lack of adequate facil-
ities and the need of training personnel, suggests the
need for develop new rapid diagnostic tools to be dir-
ectly used in rural areas. This point is extremely import-
ant in order to detect carriers after mass treatment or
vaccination.
Economic and social factors should also be considered,
as proposed at the Dahlem conference. Two points are
of special concern: the need for consensus about action,
where all organizations involved must act coordinated,
including international support, and the perception of
the illness as a pertinent public health issue.
The international support to fight against neglected
tropical diseases (NTDs) has been strongly reinforced in
the recent past. In 2012, the World Health Organization
published a report highlighting the need to advance to-
wards the control and eradication of NTDs, and alerting
about the presence of several illness that have not been
high on the global agenda [20]. Moreover, NTDs were
one of the themes of the 2015 G7 summit in Germany.
At the time, the G7 group made a firm commitment to
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advance the fight against these illnesses by supporting
research in this area and investing in prevention and
control efforts [21]. However, a disease that affects low-
to middle-income countries and poor populations in re-
mote areas and on non-touristic routes may not be per-
ceived as a priority, and may therefore not attract
sufficient interest and funding.
This lack of visibility is probably the biggest obstacle
to eradicating Carrion’s disease. Furthermore, fragmen-
ted knowledge about the illness is also a challenge: its
epidemiology is not yet fully understood, misdiagnosis
occurs due to a lack of field-based diagnostic tools and
there is a high variability in clinical symptoms [22]. The
spreading of L. verrucarum to new areas is not suffi-
ciently studied and there is a need for a proper surveil-
lance system to discover potential secondary vectors,
such as other species of Lutzomyia that are present in
other South American regions, which may account for
illness dissemination [12].
Despite adverse conditions, there are precedents in the
fight against NTD in which the knowledge about has
experimented substantial advances in short-time frame,
providing of an armamentarium which may allow to ad-
vance towards control and eradication. The Ebola is an
example, an ‘unknown’ disease that put the world on
high alert. Thanks to political and social pressure, an ef-
fective vaccine (rVSV-ZEBOV) has been developed,
which could signal the beginning of the end for massive
Ebola outbreaks [23]. Presently, the window in which
Carrion’s disease could potentially be eradicated might
be about to close due to the aforementioned expansion
of the illness to other areas. There is also risk of acciden-
tal introduction of vectors into remote areas, which can
result in the expansion of the illness to faraway areas,
similar to what Chikungunya caused in Southern Europe
or Latin America [24, 25]. In the infectious diseases
studies, pathogens that have been known during long
time, in a sudden manner irrupt in the scientific agenda.
An example is the Zika virus, a virus which is knows
from 1953. At the moment of writing these lines, middle
April 2016, we perform a PubMed research using the
words “Zika virus” being found 458 results. Of these 334
(72.9 %) were from the present year. Maybe if this virus
had been considered in a sound manner in the inter-
national research agenda prior to the last outbreak, the
current situation will be different. It is time to become
aware and act, before endemic diseases, like Carrion’s
disease, expanding and will be a risk for global health.
Conclusion
Currently, despite to be in slow expansion, Carrion’s dis-
ease, affects a well delimited geographical area, no reser-
voirs out of human has been described, antigenic
candidates will may lead to vaccine or new diagnostic
devices development have been proposed and antibiotics
has a very good activity against causing microorganism.
In summary, at present this is a potentially eradicable ill-
ness. Nonetheless, the insidious and slowly expanding
Carrion’s disease continues to scourge the Andean val-
leys, being not one of the key scientific research interest
areas globally and it is not a priority on international
health agendas.
It may be that we wait to act at the time in which the
illness arrive to touristic regions, or to big cities or when
expanded out of Andean valleys. But at that time the
windows-action will be closed.
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